{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:17:17Z","timestamp":1786997837022,"version":"build-2736575974"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.urolonc.2025.09.016","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T02:39:13Z","timestamp":1761619153000},"page":"63.e21-63.e33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Measuring what matters to patients: Systematic literature review of patient-reported outcomes assessment and reporting in locally advanced or metastatic urothelial cancer real-world and clinical studies"],"prefix":"10.1016","volume":"44","author":[{"given":"Mairead","family":"Kearney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Macmillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Poritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherrie","family":"Schreiber-Gosche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela Georgiana","family":"Musat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.09.016_bib0001","unstructured":"National Institutes of Health. Cancer stat facts: bladder cancer. Bethesda, MD. https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html. (Accessed May 25 2025)."},{"issue":"5","key":"10.1016\/j.urolonc.2025.09.016_bib0002","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.eururo.2021.01.032","article-title":"Quality of life after bladder cancer: a cross-sectional survey of patient-reported outcomes","volume":"79","author":"Catto","year":"2021","journal-title":"Eur Urol"},{"issue":"6_supp","key":"10.1016\/j.urolonc.2025.09.016_bib0003","article-title":"Understanding drivers of treatment preferences in locally advanced or metastatic urothelial carcinoma: a qualitative interview study with patients, caregivers, and physicians","volume":"41","author":"Apolo","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2025.09.016_bib0004","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1002\/cncr.23968","article-title":"Cancer patient preferences for quality and length of life","volume":"113","author":"Meropol","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2025.09.016_bib0005","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/PROM.S156279","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimization","volume":"9","author":"Mercieca-Bebber","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.urolonc.2025.09.016_bib0006","unstructured":"European Association of Urology. EAU Guidelines: muscle-invasive and metastatic bladder cancer. https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer\/chapter\/introduction. (Accessed May 25 2025)."},{"key":"10.1016\/j.urolonc.2025.09.016_bib0007","doi-asserted-by":"crossref","first-page":"101953","DOI":"10.1016\/j.eclinm.2023.101953","article-title":"Analysis of patient-reported outcomes in the approval of novel oncology drugs in the United States, 2017-2022","volume":"59","author":"Ge","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"4","key":"10.1016\/j.urolonc.2025.09.016_bib0008","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.eururo.2022.06.007","article-title":"Time to rethink quality of life assessment in patients with urothelial cancer in the current therapeutic era?","volume":"83","author":"Bergerot","year":"2023","journal-title":"European Urology"},{"issue":"8","key":"10.1016\/j.urolonc.2025.09.016_bib0009","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1007\/s10147-024-02526-y","article-title":"Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution","volume":"29","author":"Kawashima","year":"2024","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.09.016_bib0010","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/MOU.0000000000000894","article-title":"Health-related quality of life in bladder cancer patients: bladder cancer-specific instruments and domains. Part 2","volume":"31","author":"Zimmermann","year":"2021","journal-title":"Curr Opin Urology"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.016_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.urolonc.2025.09.016_bib0012","unstructured":"Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.4. www.training.cochrane.org\/handbook. (Accessed May 25 2025)."},{"issue":"8","key":"10.1016\/j.urolonc.2025.09.016_bib0013","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.urolonc.2025.09.016_bib0014","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.annonc.2022.12.004","article-title":"Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit","volume":"34","author":"Oosting","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.09.016_bib0015","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s10147-019-01563-2","article-title":"Influence of pretreatment quality of life on prognosis in patients with urothelial carcinoma","volume":"25","author":"Suppanuntaroek","year":"2020","journal-title":"Int J Clin Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2025.09.016_bib0016","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1002\/cncr.10990","article-title":"Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy","volume":"97","author":"Nogu\u00e9-Aliguer","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.016_bib0017","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000055202","article-title":"Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma \u2013 prognostic factors for response and improvement of quality of life","volume":"25","author":"Albers","year":"2002","journal-title":"Oncol Res Treat"},{"issue":"9","key":"10.1016\/j.urolonc.2025.09.016_bib0018","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.3390\/jcm10091852","article-title":"Patient-reported outcomes, health-related quality of life, and clinical outcomes for urothelial cancer patients receiving chemo- or immunotherapy: a real-life experience","volume":"10","author":"Taarnh\u00f8j","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.016_bib0019","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000526962","article-title":"Prospective evaluation of health-related quality of life in patients with metastatic urothelial carcinoma undergoing immunotherapy with pembrolizumab: symptom burden can predict survival","volume":"107","author":"Schneidewind","year":"2023","journal-title":"Urol Int"},{"issue":"9","key":"10.1016\/j.urolonc.2025.09.016_bib0020","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.21873\/anticanres.16594","article-title":"Efficacy and tolerability of enfortumab vedotin for metastatic urothelial carcinoma: early experience in the real world","volume":"43","author":"Minato","year":"2023","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.016_bib0021","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000338770","article-title":"Intermittent chemotherapy is a treatment choice for advanced urothelial cancer","volume":"83","author":"Onishi","year":"2012","journal-title":"Oncology"},{"issue":"2","key":"10.1016\/j.urolonc.2025.09.016_bib0022","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2185\/jrm.2940","article-title":"A pilot study of gemcitabine and paclitaxel as third-line chemotherapy in metastatic urothelial carcinoma","volume":"12","author":"Naiki","year":"2017","journal-title":"J Rural Med"},{"key":"10.1016\/j.urolonc.2025.09.016_bib0023","doi-asserted-by":"crossref","first-page":"100245","DOI":"10.1016\/j.ctarc.2020.100245","article-title":"Effectiveness of continuous monitoring by activity tracker of patients undergoing chemotherapy for urothelial carcinoma","volume":"25","author":"Sugiyama","year":"2020","journal-title":"Cancer Treatment Res Commun"},{"issue":"17","key":"10.1016\/j.urolonc.2025.09.016_bib0024","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.09.016_bib0025","doi-asserted-by":"crossref","first-page":"E28","DOI":"10.3816\/CGC.2009.n.018","article-title":"Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study","volume":"7","author":"Joly","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2025.09.016_bib0026","doi-asserted-by":"crossref","unstructured":"Shah M., Devine J., Wang S., et al. Patient-reported symptoms and impacts of locally advanced or metastatic urothelial cancer (la\/mUC) after chemotherapy followed by a PD-1\/PD-L1 checkpoint inhibitor (CPI). J Clin Oncol 2019;37(7_suppl); Abstract 380.","DOI":"10.1200\/JCO.2019.37.7_suppl.380"},{"key":"10.1016\/j.urolonc.2025.09.016_bib0027","doi-asserted-by":"crossref","first-page":"S480","DOI":"10.1016\/j.jval.2020.08.463","article-title":"Qualitative analysis of PAIN in patients with locally advanced or metastatic urothelial cancer","volume":"23","author":"Shah","year":"2020","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.016_bib0028","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3233\/BLC-211518","article-title":"Qualitative analysis of pain in patients with locally advanced or metastatic urothelial carcinoma","volume":"8","author":"Martin","year":"2022","journal-title":"Bladder Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2025.09.016_bib0029","first-page":"86","article-title":"Measuring priority symptoms in advanced bladder cancer: development and initial validation of a brief symptom index","volume":"11","author":"Jensen","year":"2013","journal-title":"J Support Oncol"},{"issue":"27","key":"10.1016\/j.urolonc.2025.09.016_bib0030","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","article-title":"Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract","volume":"27","author":"Bellmunt","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.09.016_bib0031","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC Study 30986","volume":"30","author":"De Santis","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.09.016_bib0032","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1007\/s12032-012-0216-x","article-title":"A phase II trial of temsirolimus in second-line metastatic urothelial cancer","volume":"29","author":"Gerullis","year":"2012","journal-title":"Med Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.09.016_bib0033","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3233\/BLC-211592","article-title":"A phase 2 study of S-588410 maintenance monotherapy for platinum-treated advanced or metastatic urothelial carcinoma","volume":"8","author":"Shimizu","year":"2022","journal-title":"Bladder Cancer"},{"issue":"19","key":"10.1016\/j.urolonc.2025.09.016_bib0034","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine\u2013cisplatin in advanced urothelial carcinoma","volume":"389","author":"Van Der Heijden","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.016_bib0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/cncr.35025","article-title":"Reliability, validity, and change thresholds of the NCCN\/FACT Bladder Symptom Index (NFBlSI-18) in patients with advanced urothelial cancer","volume":"130","author":"Peipert","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2025.09.016_bib0036","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","article-title":"General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the United States","volume":"107","author":"Nolte","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2025.09.016_bib0037","doi-asserted-by":"crossref","unstructured":"Gupta S, Loriot Y, van der Heijden MS, et al. Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la\/mUC). J Clin Oncol 2024;42(16_suppl):Abstract 4502.","DOI":"10.1200\/JCO.2024.42.16_suppl.4502"},{"key":"10.1016\/j.urolonc.2025.09.016_bib0038","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejca.2019.08.033","article-title":"Vinflunine\/gemcitabine versus carboplatin\/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: a randomised phase II trial (VINGEM)","volume":"127","author":"Holmsten","year":"2020","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.urolonc.2025.09.016_bib0039","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.23.01547","article-title":"Patient-reported outcomes in patients with advanced urothelial cancer who are ineligible for cisplatin and treated with first-line enfortumab vedotin alone or with pembrolizumab","volume":"42","author":"Milowsky","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10122","key":"10.1016\/j.urolonc.2025.09.016_bib0040","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.urolonc.2025.09.016_bib0041","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.urolonc.2025.09.016_bib0042","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1200\/JCO.2017.76.9562","article-title":"Health-related quality-of-life analysis from KEYNOTE-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer","volume":"36","author":"Vaughn","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.016_bib0043","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12894-020-00752-w","article-title":"Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)","volume":"20","author":"Necchi","year":"2020","journal-title":"BMC Urol"},{"issue":"9","key":"10.1016\/j.urolonc.2025.09.016_bib0044","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1442-2042.2007.01831.x","article-title":"Paclitaxel carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases","volume":"14","author":"Soga","year":"2007","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2025.09.016_bib0045","unstructured":"ClinicalTrials.gov. A study of atezolizumab in locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract. https:\/\/clinicaltrials.gov\/study\/NCT02928406. (Accessed March 25 2025)."},{"issue":"5","key":"10.1016\/j.urolonc.2025.09.016_bib0046","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.eururo.2022.01.032","article-title":"Health-related quality of life of patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin after platinum and PD-1\/PD-L1 inhibitor therapy: results from cohort 1 of the phase 2 EV-201 clinical trial","volume":"81","author":"McGregor","year":"2022","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.09.016_bib0047","doi-asserted-by":"crossref","first-page":"256.e15","DOI":"10.1016\/j.urolonc.2016.02.002","article-title":"Quality of life in patients with cisplatin-resistant urothelial cancer: typical ailments and effect of paclitaxel-based salvage therapy","volume":"34","author":"Niegisch","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.09.016_bib0048","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell PH, Balar AV, Vuky J, et al. First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): response and survival results up to five years from the KEYNOTE-052 phase 2 study. J Clin Oncol 2021;39(15_suppl): Abstract 4508.","DOI":"10.1200\/JCO.2021.39.15_suppl.4508"},{"issue":"6","key":"10.1016\/j.urolonc.2025.09.016_bib0049","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.eururo.2024.01.007","article-title":"Health-related quality of life in patients with previously treated advanced urothelial carcinoma from EV-301: a phase 3 trial of enfortumab vedotin versus chemotherapy","volume":"85","author":"Rosenberg","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.09.016_bib0050","doi-asserted-by":"crossref","unstructured":"Annakib S., Bekoy Y.D., Chevallier T., et al. Patient-reported outcomes for patients with locally advanced or metastatic urothelial carcinoma under pembrolizumab: a prospective multicenter observational study. J Clin Oncol 2023;41(6_suppl): Abstract 490.","DOI":"10.1200\/JCO.2023.41.6_suppl.490"},{"issue":"4","key":"10.1016\/j.urolonc.2025.09.016_bib0051","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.eururo.2022.04.016","article-title":"Patient-reported outcomes from JAVELIN Bladder 100: avelumab first-line maintenance plus best supportive care versus best supportive care alone for advanced urothelial carcinoma","volume":"83","author":"Grivas","year":"2023","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.09.016_bib0052","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s11136-020-02650-y","article-title":"US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples","volume":"30","author":"Jiang","year":"2021","journal-title":"Qual Life Res"},{"issue":"2","key":"10.1016\/j.urolonc.2025.09.016_bib0053","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/MLR.0b013e318184759e","article-title":"Comparison of population health status in six european countries: results of a representative survey using the EQ-5D questionnaire","volume":"47","author":"Konig","year":"2009","journal-title":"Med Care"},{"issue":"24","key":"10.1016\/j.urolonc.2025.09.016_bib0054","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1097\/00007632-200012150-00008","article-title":"User\u2019s manual for the SF-36v2\u2122 Health Survey","volume":"25","author":"Ware","year":"2007","journal-title":"Spine"},{"issue":"10","key":"10.1016\/j.urolonc.2025.09.016_bib0055","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s12032-015-0683-y","article-title":"Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer","volume":"32","author":"Miyata","year":"2015","journal-title":"Med Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.09.016_bib0056","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/cncr.32532","article-title":"Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced\/metastatic urothelial carcinoma treated with durvalumab in phase 1\/2 dose-escalation study 1108","volume":"126","author":"O\u2019Donnell","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2025.09.016_bib0057","unstructured":"Canadian Agency for Drugs and Technologies in Health. Pan-Canadian Oncology Drug Review final clinical guidance report. Pembrolizumab (Keytruda) for metastatic urothelial carcinoma. 2018."},{"key":"10.1016\/j.urolonc.2025.09.016_bib0058","unstructured":"ClinicalTrials.gov. A study of ramucirumab (LY3009806) plus docetaxel in participants with urothelial cancer (RANGE). https:\/\/clinicaltrials.gov\/study\/NCT02426125. (Accessed March 25 2025)."},{"issue":"11","key":"10.1016\/j.urolonc.2025.09.016_bib0059","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1007\/s00520-019-04709-0","article-title":"Validity and performance of the Functional Assessment of Cancer Therapy-Bladder (FACT-Bl) among advanced urothelial cancer patients","volume":"27","author":"Degboe","year":"2019","journal-title":"Supportive Care in Cancer"},{"key":"10.1016\/j.urolonc.2025.09.016_bib0060","unstructured":"Institute for Quality and Efficiency in Health Care. Enfortumab vedotin (urothelial carcinoma) \u2013 benefit assessment according to \u00a735a social code book V. 2022 (Accessed May 25 2025)."},{"key":"10.1016\/j.urolonc.2025.09.016_bib0061","doi-asserted-by":"crossref","unstructured":"Morales-Barrera R, Castellano DE, O'Donnell P.H, et al. Health-related quality of life (HRQoL) for patients with advanced\/metastatic urothelial carcinoma (UC) enrolled in KEYNOTE-052 who are potentially platinum ineligible. J Clin Oncol 2022;40(16_suppl):4561.","DOI":"10.1200\/JCO.2022.40.16_suppl.4561"},{"issue":"9","key":"10.1016\/j.urolonc.2025.09.016_bib0062","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s10147-019-01450-w","article-title":"Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses","volume":"24","author":"Ohyama","year":"2019","journal-title":"Int J Clin Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2025.09.016_bib0063","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1001\/jamaoncol.2020.3927","article-title":"Efficacy and safety of nab-paclitaxel vs paclitaxel on survival in patients with platinum-refractory metastatic urothelial cancer: the Canadian Cancer Trials Group BL.12 randomized clinical trial","volume":"6","author":"Sridhar","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2025.09.016_bib0064","doi-asserted-by":"crossref","unstructured":"Bamias A, De Santis M, Arranz JA, et al. Patient-reported outcomes (PROs) from IMvigor130: a global, randomised, partially blinded phase III study of atezolizumab (atezo) + platinum-based chemotherapy (PBC) vs placebo (PBO) + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC). Ann Oncol 2020;31(4_suppl):S551-S552.","DOI":"10.1016\/j.annonc.2020.08.770"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.016_bib0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(23)00540-5","article-title":"Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study","volume":"25","author":"Grande","year":"2024","journal-title":"Lancet Oncol"},{"issue":"29","key":"10.1016\/j.urolonc.2025.09.016_bib0066","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.urolonc.2025.09.016_bib0067","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.016_bib0068","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bju.16241","article-title":"Gemcitabine\/nab-paclitaxel vs gemcitabine\/carboplatin for advanced urothelial carcinoma","volume":"134","author":"An","year":"2024","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.urolonc.2025.09.016_bib0069","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.21873\/invivo.11725","article-title":"Four-weekly low-dose gemcitabine and paclitaxel in patients with platinum-resistant urothelial cancer and performance status 2\/3","volume":"33","author":"Araki","year":"2019","journal-title":"In Vivo"},{"key":"10.1016\/j.urolonc.2025.09.016_bib0070","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2023.04.027","article-title":"Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: a synthesis across 21 clinical trials involving nine different cancer types","volume":"188","author":"Musoro","year":"2023","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2025.09.016_bib0071","first-page":"110","article-title":"The role of health-related quality of life in improving cancer outcomes","volume":"9","author":"Nolazco","year":"2023","journal-title":"J Clin Transl Res"},{"key":"10.1016\/j.urolonc.2025.09.016_bib0072","unstructured":"United States Food and Drug Administration. Core patient-reported outcomes in cancer clinical trials guidance for industry. https:\/\/www.fda.gov\/media\/149994\/download?attachment. 2024 (Accessed March 25 2025)."},{"key":"10.1016\/j.urolonc.2025.09.016_bib0073","unstructured":"European Medicines Agency. Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man. The use of patient-reported outcome (PRO) measures in oncology studies. https:\/\/www.ema.europa.eu\/en\/documents\/other\/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf. 2016 (Accessed February 11 2025)."}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925003849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925003849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:30:33Z","timestamp":1773891033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925003849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1078143925003849"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.09.016","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Measuring what matters to patients: Systematic literature review of patient-reported outcomes assessment and reporting in locally advanced or metastatic urothelial cancer real-world and clinical studies","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}